OpportunityTitle: Alzheimer&apos;s Disease Therapeutics Program (U01)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description: The goal of this Funding Opportunity Announcement (FOA) is to provide support for investigators to develop new drugs for the prevention or treatment of Alzheimers disease (AD). Specifically, this initiative is aimed at researchers who have promising small molecule compounds but lack outside drug development expertise and infrastructure support to advance these compounds to the clinic. This Alzheimers Disease Therapeutics Program adjunct to the NIH Blueprint Neurotherapeutics Program will allow investigators access to a virtual pharma network of contract research organizations, technical and regulatory experts and project managers, with extensive biopharma-industry experience. The long-term goal of the Alzheimers Disease Therapeutics Program is to advance projects from medicinal chemistry optimization through Phase l clinical trials and facilitate industry partnership for their further development.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;